6533b829fe1ef96bd128980c
RESEARCH PRODUCT
Active immunotherapy of stage IV renal cell cancer using autologous tumor cells
Günther H. JacobiK. F. KlippelR. HohenfellnerT. SchärfeE. Bechtsubject
OncologyNephrologymedicine.medical_specialtyKidneymedicine.drug_classbusiness.industryUrologymedicine.medical_treatmentImmunotherapyActive immunotherapyMonoclonal antibodymedicine.diseaseNephrectomySurgerymedicine.anatomical_structureRenal cell carcinomaInternal medicinemedicineCarcinomabusinessdescription
A total of 53 patients with stage IV renal cell carcinoma were treated by vaccination with autologous tumor cells in Candida-antigen after palliative tumor nephrectomy. Follow-up has been up to 9 years. Complete remission within 48 months after nephrectomy was observed in 3 patients, while 6 showed partial remission and 18 are stable with disease. Of 26 patients with rapid progression, 17 died within 1 year after operation. The best response was seen in metastases to the liver and lung. CNS-lesions or bone metastases do not appear to respond to this treatment. We conclude that this mode of therapy is beneficiary to a certain group of patients and should be offered, as no severe side effects have been observed so far. Whether new perspectives of adoptive immunotherapy using tumor-specific monoclonal antibodies or recombinant interferons will prove effective remains to be seen.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 1986-01-01 | World Journal of Urology |